Carcinotech publishes research on patient-derived 3D-printed tumors as a breakthrough tool for drug development

Advances in tissue engineering and 3D bioprinting have revolutionized the development of physiologically relevant 3D in vitro cancer models, offering a closer representation of the tumor microenvironment (TME) and enabling high-throughput drug screening.

Image Credit: Carcinotech

In a recent study conducted by Carcinotech, we explored whether a 3D-printed lung cancer model developed using our proprietary methodologies could serve as a valuable tool for pre-clinical research and drug development.This research was first presented at the 2024 European Association for Cancer Research Annual Congress in Rotterdam and subsequently published in Molecular Oncology.

Goals and findings

Our novel approach involves developing a patient-derived, 3D-printed lung cancer model.We utilized cells from patient cancer biopsies, including critical TME components, to replicate the TME accurately. Patient tumor biopsies were processed and sectioned into FFPE blocks, with TME assessed using immunofluorescence (IF). Patient-derived cells were cultured and 3D-bioprinted with custom TME bioink onto 96-well plates. After 14 days, we characterized the 3D model composition, ensuring it mirrored the original tumor. Additionally, we tested immunotherapeutic and standard care treatments, observing changes in cellular composition through viability, cytotoxicity, apoptosis assays, and IF microscopy.

Conclusion

Our findings demonstrate that the novel, patient-derived, 3D-printed lung cancer models successfully replicate the TME with high accuracy.Through comprehensive characterization, we confirmed the presence of initial cell types and immune components in the 3D prints, maintaining their integrity 14 days post-printing.Additionally, the models responded effectively to standard and immunotherapeutic treatments, underscoring their potential as platforms for high-throughput drug discovery and screening.These advanced 3D constructs represent a significant step forward in developing novel and combinatorial cancer therapies.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Carcinotech. (2024, August 30). Carcinotech publishes research on patient-derived 3D-printed tumors as a breakthrough tool for drug development. News-Medical. Retrieved on October 07, 2024 from https://www.news-medical.net/news/20240830/Carcinotech-publishes-research-on-patient-derived-3D-printed-tumors-as-a-breakthrough-tool-for-drug-development.aspx.

  • MLA

    Carcinotech. "Carcinotech publishes research on patient-derived 3D-printed tumors as a breakthrough tool for drug development". News-Medical. 07 October 2024. <https://www.news-medical.net/news/20240830/Carcinotech-publishes-research-on-patient-derived-3D-printed-tumors-as-a-breakthrough-tool-for-drug-development.aspx>.

  • Chicago

    Carcinotech. "Carcinotech publishes research on patient-derived 3D-printed tumors as a breakthrough tool for drug development". News-Medical. https://www.news-medical.net/news/20240830/Carcinotech-publishes-research-on-patient-derived-3D-printed-tumors-as-a-breakthrough-tool-for-drug-development.aspx. (accessed October 07, 2024).

  • Harvard

    Carcinotech. 2024. Carcinotech publishes research on patient-derived 3D-printed tumors as a breakthrough tool for drug development. News-Medical, viewed 07 October 2024, https://www.news-medical.net/news/20240830/Carcinotech-publishes-research-on-patient-derived-3D-printed-tumors-as-a-breakthrough-tool-for-drug-development.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.